Alphabetical Sort


Erleada® (08-3-2018)

Class: Hormonal therapy Generic Name: Apalutamide Trade Name: Erleada® How is this drug used? Erleada is used for the treatment of patients with castration-resistant prostate cancer that has not metastasized. What is the mechanism of action? Erleada... Continue Reading

Apalutamide (08-3-2018)

Class: Hormonal therapy Generic Name: Apalutamide Trade Name: Erleada® How is this drug used? Erleada is used for the treatment of patients with castration-resistant prostate cancer that has not metastasized. What is the mechanism of action? Erleada... Continue Reading

Xtandi® (08-3-2018)

Class: Hormonal therapy Generic Name: Enzalutamide Trade Name: Xtandi® How is this drug used? Xtandi is used for the treatment of castration-resistant prostate cancer. What is the mechanism of action? Xtandi interferes with the ability of male hormones... Continue Reading

Enzalutamide (08-3-2018)

Class: Hormonal therapy Generic Name: Enzalutamide Trade Name: Xtandi® How is this drug used? Xtandi is used for the treatment of castration-resistant prostate cancer. What is the mechanism of action? Xtandi interferes with the ability of male hormones... Continue Reading

Venclexta® (08-3-2018)

Class: Biological Therapy Generic Name: Venetoclax Trade Name: Venclexta® How is this drug used? Venclexta is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a specific chromosomal... Continue Reading

Venetoclax (08-3-2018)

Class: Biological Therapy Generic Name: Venetoclax Trade Name: Venclexta® How is this drug used? Venclexta is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a specific chromosomal... Continue Reading

Enorafenib (08-3-2018)

Class: Biological Therapy Generic Name: Enorafenib Trade Name: Braftovi For which conditions is this drug approved? BRAFTOVI is approved in combination with Mektovi® (binimetinib) for the treatment of melanoma with a BRAF V600E or V600K mutation [as... Continue Reading

Braftovi (08-3-2018)

Class: Biological Therapy Generic Name: Enorafenib Trade Name: Braftovi For which conditions is this drug approved? BRAFTOVI is approved in combination with Mektovi® (binimetinib) for the treatment of melanoma with a BRAF V600E or V600K mutation [as... Continue Reading

abemaciclib (01-17-2018)

Generic Name: abemaciclib Trade Name: Verzenio For which conditions is this drug approved? Verzenio is indicated for use: In combination with fulvestrant in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer... Continue Reading

Verzenio™ (01-17-2018)

Generic Name: abemaciclib Trade Name: Verzenio For which conditions is this drug approved? Verzenio is indicated for use: In combination with fulvestrant in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer... Continue Reading

Next Page »